Scientist writing results in lab_cropped.jpg

Published Papers

Here are published papers from Dr. Nagourney, his team here at the Nagourney Cancer Institute (formerly Rational Therapeutics) and colleagues from around the world.

Since founding Rational Therapeutics (now Nagourney Cancer Institute) over 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD) functional profiling assay, general cancer research, and the effectiveness of new drugs and combinations.

Dr. Nagourney himself has AUTHORED more than 100 manuscripts, book chapters and abstracts including publications in the JOURNAL OF CLINICAL ONCOLOGY, GYNECOLOGIC ONCOLOGYTHE JOURNAL OF THE NATIONAL CANCER INSTITUTE. and BRITISH JOURNAL OF CANCER.

We have selected a few of our most prominent papers to make available for download on this site.

* NEW* Our exciting latest paper just released August 2018 reported that it was possible to identify who would develop breast cancer with >95% accuracy from looking at only a drop of blood.  It was an international study of over 1,200 patients looking at over almost 200 chemicals in the blood stream and finding differences between “normal” patients and those that developed breast cancer.

This means that it may be possible to predict who is on the way to getting breast cancer and could suggest ways to make diet and lifestyle changes to prevent ever getting breast cancer.

Curves.png

Survival Curves

Comparing the survival of patients who tested sensitive to the agents they received, compared with those who were found resistant to the treatments that they received.
document.png

Clinical Application of Assay-Directed Therapy

Predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.
Information.png

Physician Information

Find out how you can receive specific information on how your patient’s cancer cells will react to single agents, combinations or targeted therapies.